Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis

Inclusion Criteria: Clinically diagnosed Oral Submucous Fibrosis (OSF), Stage II-IV using Haider et al. classification. Age 18-65 years. Mouth opening ≤ 30 mm. Persistent burning sensation (VAS ≥ 3). Able and willing to comply with weekly therapy sessions. Provided written informed consent. Exclusion Criteria: Previous treatment with PRP, Platelet-rich Fibrin (PRF), corticosteroid, or combination therapy in the last 6 months. Systemic diseases affecting wound healing (e.g., uncontrolled diabetes, severe anemia). Current steroid therapy or immunosuppressive therapy. Oral lesions suspicious for malignancy or recurrent Oral Squamous cell carcinoma (OSCC). Bleeding disorders or platelet count \<150,000. Pregnant or breastfeeding women. Known allergy to local anesthetics or triamcinolone. Patients unwilling to stop areca nut/tobacco habits.